Comparative genomics allowed the identification of drug targets against human fungal pathogens.

ABSTRACT:

Background

The prevalence of invasive fungal infections (IFIs) has increased steadily worldwide in the last few decades. Particularly, there has been a global rise in the number of infections among immunosuppressed people. These patients present severe clinical forms of the infections, which are commonly fatal, and they are more susceptible to opportunistic fungal infections than non-immunocompromised people. IFIs have historically been associated with high morbidity and mortality, partly because of the limitations of available antifungal therapies, including side effects, toxicities, drug interactions and antifungal resistance. Thus, the search for alternative therapies and/or the development of more specific drugs is a challenge that needs to be met. Genomics has created new ways

SUBMITTER: Abadio AK 

PROVIDER: S-EPMC3042012 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature